AYTU AYTU BioPharma Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934  

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

 

Check the appropriate box:

 

☐						Preliminary Proxy Statement
☐						Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐						Definitive Proxy Statement
☒						Definitive Additional Materials
☐						Soliciting Material Pursuant to § 240.14a-12

Aytu BioPharma, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

☒

No fee required.

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

 

 

 

 

 

 

---

 

 

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

☐

Fee paid previously with preliminary materials.

☐

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount Previously Paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:

 

 

a

AYTU BIOPHARMA, INC.

 

373 Inverness Parkway, Suite 206

 

Englewood, Colorado 80112

 

May 19, 2021

 

Dear Aytu Stockholder:

 

The proxy statement of the 2021 Annual Meeting of the Stockholders (the “Proxy Statement”) of Aytu BioPharma, Inc., a Delaware corporation (the “Company”), to be held on May 21, 2021 (the “Meeting”), was filed with the Securities and Exchange Commission on April 19, 2021. Since then, there have been developments regarding the Board of Directors of the Company (the “Board”). This communication describes these recent events and supplements portions of the Proxy Statement as set forth in this supplement to the Proxy Statement.

 

Recent Developments

 

On May 17, 2021, the Board accepted the resignations of Beth Hecht and Gerald McLaughlin from the Board, effective as of May 17, 2021.

 

Impact on Voting at the Meeting

 

Stockholders do not need to take any action if they have already voted their shares for the Meeting. The nominees named in the Proxy Statement sent or made available to the Company’s stockholders will stand for election at the Meeting. The form of proxy card included in the Company’s definitive proxy materials remains valid, and no new proxy cards are being distributed.

 

Thank you for your ongoing support of and continued interest in Aytu BioPharma, Inc.

 

 

Sincerely, /s/ Joshua Disbrow       Joshua R. Disbrow Chairman and Chief Executive Officer